LivingGLP1
parallel randomized trial

NCT04440345

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obese Subjects

Design

Randomized
60
Start year
2020
Treatment
12 weeks, follow-up 20 weeks
Countries
China (6 sites)
Sponsor
Innovent Biologics (industry)
Eligibility
age 18 to 75; BMI 28 or more, or 24 to below 28 with hyperphagia or comorbidity; diabetes excluded

Conduct and analysis

Blinding
double blind
Sequence generation
other adequate
Allocation concealment
central
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
safety
Missing data
MMRM without imputation

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Mazdutide 3 mg subcutaneous once weekly
IBI362 3.0 mg cohort
lifestyle: none88
A10Mazdutide 9 mg subcutaneous once weekly
Mazdutide 9 mg cohort
lifestyle: none888
A11Placebo
Placebo 9 mg cohort
lifestyle: none444
A12Pooled
Pooled placebo 9 and 10 mg cohorts
lifestyle: none8
A13Pooled
Pooled IBI362 3.0 to 6.0 mg cohorts
lifestyle: none24
A2Placebo
Placebo 3.0 mg cohort
lifestyle: none44
A3Mazdutide 4.5 mg subcutaneous once weekly
IBI362 4.5 mg cohort
lifestyle: none88
A4Placebo
Placebo 4.5 mg cohort
lifestyle: none44
A5Mazdutide 6 mg subcutaneous once weekly
IBI362 6.0 mg cohort
lifestyle: none88
A6Placebo
Placebo 6.0 mg cohort
lifestyle: none44
A7Pooled
Pooled placebo 3.0 to 6.0 mg cohorts
lifestyle: none12
A8mazdutide
Mazdutide 10 mg cohort
lifestyle: none887
A9Placebo
Placebo 10 mg cohort
lifestyle: none442

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticMazdutide 3 mg subcutaneous once weekly
A1
Placebo
A2
Mazdutide 4.5 mg subcutaneous once weekly
A3
Placebo
A4
Mazdutide 6 mg subcutaneous once weekly
A5
Placebo
A6
Pooled
A7
Mazdutide 10 mg cohort
A8
Placebo
A9
Mazdutide 9 mg subcutaneous once weekly
A10
Placebo
A11
Pooled
A12
Pooled
A13
agemean (years)36.034.337.945.5
agemedian (years)29.539.531.037.040.032.0
ageq1 (years)24.031.023.532.523.028.5
ageq3 (years)45.043.533.043.051.534.5
agesd (years)9.114.09.76.4
asiann848484
asianpercent100.0100.0100.0100.0100.0100.0
bmi: 24 to less than 28n201103
bmi: 24 to less than 28percent25.0012.525.0075.0
bmi: 28 or moren647381
bmi: 28 or morepercent75.0100.087.575.010025.0
bmimean (kg/m2)29.330.632.429.131.729.031.829.130.130.1
bmisd (kg/m2)2.21.23.43.72.05.15.14.63.81.7
femalen5322336362
femalepercent62.575.025.050.037.575.075.075.075.050.0
waistmean (cm)93.495.1105.198.1104.890.1101.195.097.2105.1
waistsd (cm)8.92.08.010.510.214.911.511.713.77.7
weightmean (kg)78.381.793.182.787.476.582.877.279.883.6
weightsd (kg)13.73.39.913.78.821.514.118.615.57.3

Results

198 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Systolic blood pressure change (4 lines; O05)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A1change-8.26 mmHg-14.77 to -1.768not stated; modified itt; R0014885:Table 4
12A3change-5.80 mmHg-12.34 to 0.738not stated; modified itt; R0014885:Table 4
12A5change-5.59 mmHg-12.56 to 1.387not stated; modified itt; R0014885:Table 4
12A7change2.02 mmHg-3.40 to 7.4412not stated; modified itt; R0014885:Table 4
Percent body weight change (13 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A1percent change-4.81 percent-6.61 to -3.028not stated; modified itt; R0014885:Table 4
12A1 vs A7md-5.42 percent-7.71 to -3.12not stated; modified itt; R0014885:Table 4
12A10percent change-11.7 percent1.5not stated; modified itt; R0013351:Table 4
12A10 vs A12md-9.8 percent-14.4 to -5.3not stated; modified itt; R0013351:Table 4
12A12percent change-1.8 percent1.6not stated; modified itt; R0013351:Table 4
12A3percent change-6.40 percent-8.23 to -4.588not stated; modified itt; R0014885:Table 4
12A3 vs A7md-7.01 percent-9.39 to -4.63not stated; modified itt; R0014885:Table 4
12A5percent change-6.05 percent-7.91 to -4.187not stated; modified itt; R0014885:Table 4
12A5 vs A7md-6.65 percent-9.03 to -4.27not stated; modified itt; R0014885:Table 4
12A7percent change0.60 percent-0.86 to 2.0712not stated; modified itt; R0014885:Table 4
16A12percent change-3.3 percent1.9not stated; modified itt; R0013351:Table 4
16A8percent change-9.5 percent1.7not stated; modified itt; R0013351:Table 4
16A8 vs A12md-6.2 percent-11.5 to -0.9not stated; modified itt; R0013351:Table 4
Weight loss of 5 percent or more (4 lines; O11A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A11responders0 / 4not stated; modified itt; R0013351:Results
12A13responders13 / 24not stated; modified itt; R0014885:Results
12A7responders0 / 12not stated; modified itt; R0014885:Results
16A9responders0 / 4not stated; modified itt; R0013351:Results
Weight loss of 10 percent or more (5 lines; O11B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A10responders4 / 8not stated; modified itt; R0013351:Results
12A11responders0 / 4not stated; modified itt; R0013351:Results
12A7responders0 / 12not stated; modified itt; R0014885:Results
16A8responders4 / 8not stated; modified itt; R0013351:Results
16A9responders0 / 4not stated; modified itt; R0013351:Results
Weight loss of 15 percent or more (5 lines; O11C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
12A10responders2 / 8not stated; modified itt; R0013351:Results
12A11responders0 / 4not stated; modified itt; R0013351:Results
12A7responders0 / 12not stated; modified itt; R0014885:Results
16A8responders2 / 8not stated; modified itt; R0013351:Results
16A9responders0 / 4not stated; modified itt; R0013351:Results
Acute kidney injury (4 lines; O121)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A2events0 / 4not stated; safety; R0014885:Supplement Table S2
A4events0 / 4not stated; safety; R0014885:Supplement Table S2
A5events0 / 8not stated; safety; R0014885:Supplement Table S2
A6events0 / 4not stated; safety; R0014885:Supplement Table S2
All cause mortality (10 lines; O20)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events0 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Hospitalization for heart failure (10 lines; O23)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events0 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Heart failure events (6 lines; O23B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A11events0 / 4not stated; safety; R0013351:Supplement Table S1
A2events0 / 4not stated; safety; R0014885:Supplement Table S2
A4events0 / 4not stated; safety; R0014885:Supplement Table S2
A5events0 / 8not stated; safety; R0014885:Supplement Table S2
A6events0 / 4not stated; safety; R0014885:Supplement Table S2
A8events0 / 8not stated; safety; R0013351:Supplement Table S1
Serious adverse events (10 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events0 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Discontinuation due to adverse events (16 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Abstract
A1events0 / 8not stated; safety; R0014885:Results
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Results
A2events0 / 4not stated; safety; R0014885:Abstract
A3events0 / 8not stated; safety; R0014885:Abstract
A3events0 / 8not stated; safety; R0014885:Results
A4events0 / 4not stated; safety; R0014885:Abstract
A4events0 / 4not stated; safety; R0014885:Results
A5events0 / 8not stated; safety; R0014885:Results
A5events0 / 8not stated; safety; R0014885:Abstract
A6events0 / 4not stated; safety; R0014885:Abstract
A6events0 / 4not stated; safety; R0014885:Results
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Nausea (10 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events5 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events3 / 8not stated; safety; R0014885:Table 2
A4events1 / 4not stated; safety; R0014885:Table 2
A5events1 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events1 / 8not stated; safety; R0013351:Table 2
A9events1 / 4not stated; safety; R0013351:Table 2
Vomiting (10 lines; O27B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events1 / 8not stated; safety; R0014885:Table 2
A10events3 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events1 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events3 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Diarrhea (10 lines; O27C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events2 / 8not stated; safety; R0013351:Table 2
A11events2 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events3 / 8not stated; safety; R0014885:Table 2
A4events1 / 4not stated; safety; R0014885:Table 2
A5events3 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events4 / 8not stated; safety; R0013351:Table 2
A9events2 / 4not stated; safety; R0013351:Table 2
Constipation (10 lines; O27D)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events1 / 8not stated; safety; R0014885:Table 2
A10events1 / 8not stated; safety; R0013351:Supplement Table S1
A11events0 / 4not stated; safety; R0013351:Supplement Table S1
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events0 / 8not stated; safety; R0014885:Table 2
A6events1 / 4not stated; safety; R0014885:Table 2
A8events0 / 8not stated; safety; R0013351:Supplement Table S1
A9events0 / 4not stated; safety; R0013351:Supplement Table S1
Discontinuation due to gastrointestinal adverse events (16 lines; O27E)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Results
A1events0 / 8not stated; safety; R0014885:Abstract
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Abstract
A2events0 / 4not stated; safety; R0014885:Results
A3events0 / 8not stated; safety; R0014885:Results
A3events0 / 8not stated; safety; R0014885:Abstract
A4events0 / 4not stated; safety; R0014885:Results
A4events0 / 4not stated; safety; R0014885:Abstract
A5events0 / 8not stated; safety; R0014885:Results
A5events0 / 8not stated; safety; R0014885:Abstract
A6events0 / 4not stated; safety; R0014885:Abstract
A6events0 / 4not stated; safety; R0014885:Results
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2
Gallbladder and biliary disease (4 lines; O28)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A10events1 / 8not stated; safety; cholelithiasis; R0013351:Supplement Table S1
A11events0 / 4not stated; safety; cholelithiasis; R0013351:Supplement Table S1
A8events0 / 8not stated; safety; cholelithiasis; R0013351:Supplement Table S1
A9events0 / 4not stated; safety; cholelithiasis; R0013351:Supplement Table S1
Acute pancreatitis (10 lines; O29)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; pancreatitis; R0014885:Results
A10events0 / 8not stated; safety; pancreatitis; R0013351:Results
A11events0 / 4not stated; safety; pancreatitis; R0013351:Results
A2events0 / 4not stated; safety; pancreatitis; R0014885:Results
A3events0 / 8not stated; safety; pancreatitis; R0014885:Results
A4events0 / 4not stated; safety; pancreatitis; R0014885:Results
A5events0 / 8not stated; safety; pancreatitis; R0014885:Results
A6events0 / 4not stated; safety; pancreatitis; R0014885:Results
A8events0 / 8not stated; safety; pancreatitis; R0013351:Results
A9events0 / 4not stated; safety; pancreatitis; R0013351:Results
Medullary thyroid carcinoma (10 lines; O32A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Results
A10events0 / 8not stated; safety; R0013351:Results
A11events0 / 4not stated; safety; R0013351:Results
A2events0 / 4not stated; safety; R0014885:Results
A3events0 / 8not stated; safety; R0014885:Results
A4events0 / 4not stated; safety; R0014885:Results
A5events0 / 8not stated; safety; R0014885:Results
A6events0 / 4not stated; safety; R0014885:Results
A8events0 / 8not stated; safety; R0013351:Results
A9events0 / 4not stated; safety; R0013351:Results
Thyroid cancer (any) (10 lines; O32B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Results
A10events0 / 8not stated; safety; R0013351:Results
A11events0 / 4not stated; safety; R0013351:Results
A2events0 / 4not stated; safety; R0014885:Results
A3events0 / 8not stated; safety; R0014885:Results
A4events0 / 4not stated; safety; R0014885:Results
A5events0 / 8not stated; safety; R0014885:Results
A6events0 / 4not stated; safety; R0014885:Results
A8events0 / 8not stated; safety; R0013351:Results
A9events0 / 4not stated; safety; R0013351:Results
Nonarteritic anterior ischemic optic neuropathy (3 lines; O34)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A10events0 / 8not stated; safety; R0013351:Supplement Table S1
A11events0 / 4not stated; safety; R0013351:Supplement Table S1
A9events0 / 4not stated; safety; R0013351:Supplement Table S1
Suicidal ideation or behavior (8 lines; O35A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Supplement Table S2
A11events0 / 4not stated; safety; R0013351:Supplement Table S1
A2events0 / 4not stated; safety; R0014885:Supplement Table S2
A4events0 / 4not stated; safety; R0014885:Supplement Table S2
A5events0 / 8not stated; safety; R0014885:Supplement Table S2
A6events0 / 4not stated; safety; R0014885:Supplement Table S2
A8events0 / 8not stated; safety; R0013351:Supplement Table S1
A9events0 / 4not stated; safety; R0013351:Supplement Table S1
Death by suicide (10 lines; O35B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 8not stated; safety; R0014885:Table 2
A10events0 / 8not stated; safety; R0013351:Table 2
A11events0 / 4not stated; safety; R0013351:Table 2
A2events0 / 4not stated; safety; R0014885:Table 2
A3events0 / 8not stated; safety; R0014885:Table 2
A4events0 / 4not stated; safety; R0014885:Table 2
A5events0 / 8not stated; safety; R0014885:Table 2
A6events0 / 4not stated; safety; R0014885:Table 2
A8events0 / 8not stated; safety; R0013351:Table 2
A9events0 / 4not stated; safety; R0013351:Table 2